ScholarIQanswers from OpenAlex & ORCID
Makoto Nishio
ResearcherPublications, citations & collaboration network
Makoto Nishio is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Makoto Nishio have?
ScholarIQindexed works
Makoto Nishio has 851 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Makoto Nishio have?
ScholarIQcitation count
Makoto Nishio has 31,981 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Makoto Nishio?
ScholarIQh-index
Makoto Nishio has an h-index of 71 in OpenAlex.
What is the i10-index of Makoto Nishio?
ScholarIQi10-index
Makoto Nishio has an i10-index of 282 in OpenAlex.
What is the ORCID of Makoto Nishio?
ScholarIQorcid
The ORCID for Makoto Nishio is on the source record.
What is the OpenAlex record for Makoto Nishio?
ScholarIQopenalex
The OpenAlex for Makoto Nishio is on the source record.
What are the most-cited papers on Makoto Nishio?
ScholarIQmost cited works
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Beiying Ding, Ariel López-Chávez, Fairooz F. Kabbinavar, Wei Lin, Alan Sandler, Stephen V. Liu
Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer
Jürgen Wolf, Takashi Seto, Ji‐Youn Han, Noemı́ Reguart, Edward B. Garon, Harry J.M. Groen, Daniel S.W. Tan, Toyoaki Hida, Maja J.A. de Jonge, Sergey Orlov, Egbert F. Smit, Pierre-Jean Souquet, Johan Vansteenkiste, Maximilian J. Hochmair, Enriqueta Felip, Makoto Nishio, Michael Thomas, Kadoaki Ohashi, Ryo Toyozawa, Tobias R. Overbeck, Filippo de Marinis, Tae Min Kim, Eckart Laack, Anna Robeva, Sylvie Le Mouhaër, Maeve Waldron-Lynch, B. Sankaran, O. Alejandro Balbin, Xiaoming Cui, Monica Giovannini, Mikhail Akimov, Rebecca S. Heist
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski, Martin Reck, Tony Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura, Katsuyuki Hotta, Satoshi Watanabe, Kōichi Goto, Miyako Satouchi, Toshiyuki Kozuki, Takehito Shukuya, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, T. Asakawa, Ryoichi Asabe, Tomohiro Tanaka, Tomohide Tamura
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Luc Friboulet, Nanxin Li, Ryohei Katayama, Christian C. Lee, Justin F. Gainor, Adam Crystal, Pierre‐Yves Michellys, Mark M. Awad, Noriko Yanagitani, Sung Joon Kim, AnneMarie Culazzo Pferdekamper, Jie Li, Shailaja Kasibhatla, Frank F. Sun, Xiuying Sun, Su Hua, Peter McNamara, Sidra Mahmood, Elizabeth L. Lockerman, Naoya Fujita, Makoto Nishio, Jennifer L. Harris, Alice T. Shaw, Jeffrey A. Engelman